Justin Stebbing1, Onyinyechi Duru, Mark Bower. 1. Department of Oncology, Imperial College School of Medicine, The Chelsea and Westminster Hospital, London, UK.
Abstract
PURPOSE OF REVIEW: Individuals with HIV infection are at higher risk for the development of a wide variety of non-AIDS-defining cancers (NADCs). Immunosuppressed patients following allograft organ transplantation are also at an increased risk for most of these tumour types implicating immune suppression in the pathogenesis rather than HIV itself. Although all three AIDS-defining malignancies and many NADCs are associated with viral etiopathogenesis, some, such as lung cancer, are not related to any known viral oncogenes and the reason for their increased incidence in immunosuppressed individuals remains unclear. RECENT FINDINGS: The majority of the excess risk of NADC is accounted for by a limited number of specific cancers, which repeatedly occur with increased incidence in published series. Many of the data date from the pre-highly active antiretroviral therapy era and are thus not applicable to the 21st Century. SUMMARY: NADCs are contributing significantly to the morbidity and mortality of HIV infection in the era of highly active antiretroviral therapy and the risk of NADCs does not correlate with the degree of immunodeficiency in general.
PURPOSE OF REVIEW: Individuals with HIV infection are at higher risk for the development of a wide variety of non-AIDS-defining cancers (NADCs). Immunosuppressed patients following allograft organ transplantation are also at an increased risk for most of these tumour types implicating immune suppression in the pathogenesis rather than HIV itself. Although all three AIDS-defining malignancies and many NADCs are associated with viral etiopathogenesis, some, such as lung cancer, are not related to any known viral oncogenes and the reason for their increased incidence in immunosuppressed individuals remains unclear. RECENT FINDINGS: The majority of the excess risk of NADC is accounted for by a limited number of specific cancers, which repeatedly occur with increased incidence in published series. Many of the data date from the pre-highly active antiretroviral therapy era and are thus not applicable to the 21st Century. SUMMARY: NADCs are contributing significantly to the morbidity and mortality of HIV infection in the era of highly active antiretroviral therapy and the risk of NADCs does not correlate with the degree of immunodeficiency in general.
Authors: Fengyi Jin; Claire M Vajdic; Matthew Law; Janaki Amin; Marina van Leeuwen; Skye McGregor; I Mary Poynten; David J Templeton; Andrew E Grulich Journal: AIDS Date: 2019-07-01 Impact factor: 4.177
Authors: S Leone; G Gregis; G Quinzan; D Velenti; G Cologni; L Soavi; V Ravasio; D Ripamonti; F Suter; F Maggiolo Journal: Infection Date: 2011-01-19 Impact factor: 3.553
Authors: Marc A Kowalkowski; Rena S Day; Xianglin L Du; Wenyaw Chan; Elizabeth Y Chiao Journal: J Acquir Immune Defic Syndr Date: 2014-10-01 Impact factor: 3.731
Authors: Clare Meernik; Amr S Soliman; Twalib Ngoma; Crispin Kahesa; Julius Mwaiselage; Sofia D Merajver Journal: Infect Agent Cancer Date: 2014-12-09 Impact factor: 2.965